Precision Immunotherapy™
investors-relations
Home/Investor Relations/Press Releases
Investor Relations

Quick Links

Email Alerts

Email Address *
Mailing Lists *




 
Enter the code shown above.

Press Releases

2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
11/17/2015 Opexa Therapeutics Chosen as One of the Top Autoimmune Therapy Projects to Watch
11/10/2021 Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica (NMO) Program
11/10/2021 Opexa Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update
11/06/2022 Opexa Therapeutics Announces News Release Schedule for Third Quarter 2015 Financial Results
10/19/2015 Opexa Therapeutics to Host Analyst and Investor Event on November 10 in New York
10/15/2015 Opexa Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
10/13/2015 Opexa Therapeutics to Present at BIO Investor Forum
10/06/2022 Opexa Announces Granting of New T-cell Patents Covering Tcelna®; Patent Estate Increases to 160 Issued Patents
09/28/2015 Opexa Announces Reverse Stock Split
09/01/2022 Opexa Secures Private Funding for its NMO Orphan Development Program, Including Planned Phase I/II Clinical Study
08/28/2015 Opexa Therapeutics to Present at September Conferences
08/12/2021 Opexa Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
08/03/2022 Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2015 Financial Results
06/11/2021 Opexa Therapeutics CEO to Present at BIO 2015 International Convention
06/09/2022 Opexa Hires Experienced Pharmaceutical Executive as Vice President of Business Development
05/21/2015 Opexa Therapeutics to Present at the 2015 Marcum Microcap Conference
05/13/2015 Opexa Therapeutics CEO Invited to Participate in Multiple May Conferences
05/12/2021 Opexa Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update
05/11/2021 Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2015 Financial Results
04/20/2015 Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology (AAN) 2015 Annual Meeting
04/09/2022 Opexa Therapeutics, Inc. Announces Completion of Rights Offering
04/06/2022 Opexa Therapeutics Reminds Shareholders That Rights Offering Expires on April 8, 2022 at 5:00 PM ET
03/10/2021 Opexa Therapeutics Reminds Shareholders That Rights Offering Ownership Date and Time is Tuesday, March 10, 2022 at 4:00 PM ET
03/09/2022 Opexa Amends Agreement with Merck Serono and Receives Additional $3 Million Payment to Support Ongoing Development of Tcelna® for Multiple Sclerosis
02/25/2015 Opexa Therapeutics, Inc. Announces Record Date and Subscription Price for Rights Offering
02/23/2015 Opexa Therapeutics Reports Year End 2014 Financial Results and Provides Corporate Update
01/28/2015 Opexa Therapeutics, Inc. Files Registration Statement for Rights Offering
© 2013 Opexa Therapeutics, Inc. All Rights Reserved.
Powered By Q4 Web Systems 4.1.3.41